Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
Hodgkin lymphoma (HL) is a potentially curable lymphoma, and modern therapy is expected to successfully cure more than 80% of the patients. Second-line salvage high-dose chemotherapy and autologous stem cell transplantation (auto-SCT) have an established role in the management of refractory and rela...
Saved in:
| Main Authors: | Roberta Fedele, Massimo Martino, Anna Grazia Recchia, Giuseppe Irrera, Massimo Gentile, Fortunato Morabito |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/968212 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01) -
Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01) -
Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis
by: Mohamed Nazem Alibrahim, et al.
Published: (2025-05-01) -
The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01) -
Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma
by: Yoshito Nishimura, et al.
Published: (2025-08-01)